Switch theme
Sign up to access all valuation multiples
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
2007
11
LTM Revenue $6.7M
LTM EBITDA -$31.0M
$108M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Egetis Therapeutics has a last 12-month revenue of $6.7M and a last 12-month EBITDA of -$31.0M.
In the most recent fiscal year, Egetis Therapeutics achieved revenue of $4.6M and an EBITDA of -$32.0M.
Egetis Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Egetis Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | XXX | XXX | XXX |
| Gross Profit | -$11.9M | -$14.6M | XXX | XXX | XXX |
| Gross Margin | -209% | -319% | XXX | XXX | XXX |
| EBITDA | -$31.7M | -$32.0M | XXX | XXX | XXX |
| EBITDA Margin | -554% | -699% | XXX | XXX | XXX |
| Net Profit | -$19.2M | -$32.5M | XXX | XXX | XXX |
| Net Margin | -336% | -709% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Egetis Therapeutics's stock price is SEK 4 (or $0).
Egetis Therapeutics has current market cap of SEK 1.3B (or $131M), and EV of SEK 1.1B (or $108M).
See Egetis Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $108M | $131M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Egetis Therapeutics has market cap of $131M and EV of $108M.
Egetis Therapeutics's trades at 16.1x LTM EV/Revenue multiple, and -3.5x LTM EBITDA.
Analysts estimate Egetis Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Egetis Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $108M | XXX | XXX | XXX |
| EV/Revenue | 23.5x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEgetis Therapeutics's NTM/LTM revenue growth is 338%
Egetis Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $3.2M for the same period.
Over next 12 months, Egetis Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Egetis Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Egetis Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -699% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -361% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 238% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 229% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 317% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 773% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Egetis Therapeutics acquired XXX companies to date.
Last acquisition by Egetis Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Egetis Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Egetis Therapeutics founded? | Egetis Therapeutics was founded in 2007. |
| Where is Egetis Therapeutics headquartered? | Egetis Therapeutics is headquartered in Sweden. |
| How many employees does Egetis Therapeutics have? | As of today, Egetis Therapeutics has 11 employees. |
| Who is the CEO of Egetis Therapeutics? | Egetis Therapeutics's CEO is Mr. Nicklas Westerholm. |
| Is Egetis Therapeutics publicy listed? | Yes, Egetis Therapeutics is a public company listed on STO. |
| What is the stock symbol of Egetis Therapeutics? | Egetis Therapeutics trades under EGTX ticker. |
| When did Egetis Therapeutics go public? | Egetis Therapeutics went public in 2011. |
| Who are competitors of Egetis Therapeutics? | Similar companies to Egetis Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Egetis Therapeutics? | Egetis Therapeutics's current market cap is $131M |
| What is the current revenue of Egetis Therapeutics? | Egetis Therapeutics's last 12-month revenue is $6.7M. |
| What is the current EBITDA of Egetis Therapeutics? | Egetis Therapeutics's last 12-month EBITDA is -$31.0M. |
| What is the current EV/Revenue multiple of Egetis Therapeutics? | Current revenue multiple of Egetis Therapeutics is 16.1x. |
| What is the current EV/EBITDA multiple of Egetis Therapeutics? | Current EBITDA multiple of Egetis Therapeutics is -3.5x. |
| What is the current revenue growth of Egetis Therapeutics? | Egetis Therapeutics revenue growth between 2023 and 2024 was -20%. |
| Is Egetis Therapeutics profitable? | Yes, Egetis Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
